Online inquiry

IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12903MR)

This product GTTS-WQ12903MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FZD10 gene. The antibody can be applied in Synovial sarcoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_007197.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 11211
UniProt ID Q9ULW2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12903MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15027MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ8034MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ12624MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ13910MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ7488MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ11679MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15579MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ7583MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW